enzh-TWfrdeitjaptrues


Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.

To read more insights from the EHA Annual Congress, please visit:

https://www.oncnet.com/conference-insider/ixazomib-plus-rituximab-and-dexamethasone-safe-effective-wm